Vertex, NHS trade barbs over CF pricing

NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to resolve a stalemate over Orkambi lumacaftor/ivacaftor at their latest meeting to discuss reimbursement of the cystic fibrosis drug.

While the two parties released terse statements July 5 in the wake of a meeting on July 4, Vertex spokesperson Heather Nichols did say the company was not considering canceling English trials as it did in France recently after a similar impasse...